首发精神分裂症治疗中齐拉西酮、利培酮的效果及药物经济学分析  

Analysis of effect and pharmacoeconomics for ziprasidone and risperidone in the treatment of first-episode schizophrenia

作　　者：韩延芹 季淑梅 HAN Yan-qin;JI Shu-mei(Liaocheng Fourth People’s Hospital,Liaocheng 252000,China)

机构地区：[1]聊城市第四人民医院,252000

出　　处：《中国实用医药》2021年第16期21-23,共3页China Practical Medicine

摘　　要：目的探究首发精神分裂症治疗中齐拉西酮、利培酮的效果及药物经济学。方法234例首发精神分裂症患者,随机分为齐拉西酮组和利培酮组,每组117例。齐拉西酮组给予齐拉西酮治疗,利培酮组给予利培酮治疗。对比两组用药后的治疗效果、药物不良反应发生情况及药物经济学。结果两组患者治疗总有效率对比,差异无统计学意义(P>0.05)。齐拉西酮组用药后的不良反应发生率10.26%明显低于利培酮组的23.93%,差异具有统计学意义(P<0.05)。齐拉西酮组的成本-效果比为5.089,利培酮组为0.165,利培酮组的成本-效果比明显优于齐拉西酮组。结论对于首发精神分裂症患者的治疗,齐拉西酮与利培酮的疗效相当,但齐拉西酮安全性优于利培酮,服用齐拉西酮治疗可提高患者的生活质量及服药依从性,降低因减药、停药而致病情复发的风险。但利培酮的成本-效果比优于齐拉西酮,临床医生应结合患者的实际情况为其应用最佳治疗方案。Objective To investigate the effect and pharmacoeconomics for ziprasidone and risperidone in the treatment of first-episode schizophrenia.Methods A total of 234 patients with first-episode schizophrenia were randomly divided into ziprasidone group and risperidone group,with 117 cases in each group.Ziprasidone group was treated with ziprasidone group,and risperidone group was treated with risperidone.The therapeutic effect,occurrence of adverse drug reactions,and pharmacoeconomics were compared between the two groups.Results There was no statistically significant difference in total effective rate between the two groups(P>0.05).The incidence of adverse drug reactions 10.26%after medication of ziprasidone group was obviously lower than 23.93%of risperidone group,and the difference was statistically significant(P<0.05).The cost-effectiveness ratio of the ziprasidone group was 5.089,and the risperidone group was 0.165.The cost-effectiveness ratio of the risperidone group was significantly better than that of the ziprasidone group.Conclusion Both ziprasidone and risperidone show equal efficacy on patients with first-episode schizophrenia,but ziprasidone is safer than risperidone.Taking ziprasidone can improve the quality of life and medication compliance of patients,reduce the risk of relapse caused by drug reduction and withdrawal.However,the cost-effectiveness ratio of risperidone is better than that of ziprasidone,and clinicians should apply the best treatment plan based on the actual situation of the patient.

关 键 词：精神分裂症 齐拉西酮 利培酮 药物经济学 

分 类 号：R749.3[医药卫生—神经病学与精神病学]